Sep 12, 2023 / 02:10PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
All right. Thanks, everyone, for joining us. My name is Tejas Savant and I'm the Life Science Tools and Diagnostics Analyst at Morgan Stanley. Before we begin, I'd like to remind our listeners that important disclosure information can be found at morganstanley.com/research disclosures. So it's my pleasure today to host Charles River, and speaking on behalf of the company, we have Chairman, President and CEO, Jim Foster. Thank you for joining us today, Jim.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystMaybe to just set the stage, let's start with the biopharma funding environment. You've called out sort of stable to improving trends here in the second quarter. It's something we've heard from other life science companies as well over the last couple of days. But then on the other hand, you've also talked about I guess, an inevitable normalization following a pretty unique multiyear period of R&D budget strength. Help us think
Trustpilot
